Research Reports Coverage on Biotech Stocks -- Emergent BioSolutions, Chimerix, VIVUS, and RXi Pharma

News provided by

Jan 18, 2017, 01:15 ET

NEW YORK, January 18, 2017 /PRNewswire/ --

Stock-Callers.com today has issued research reports on four Biotechnology equities, which are Emergent BioSolutions Inc. (NYSE: EBS), Chimerix Inc. (NASDAQ: CMRX), VIVUS Inc. (NASDAQ: VVUS), and RXi Pharmaceuticals Corp. (NASDAQ: RXII). These stocks are part of the Healthcare sector which continued to ail on Tuesday, January 17^th, 2017, with the NYSE Health Care Index declining about 0.6%, while shares of health care companies in the S&P 500 also were down 0.6% as a group. These stocks research reports can be downloaded now by simply registering for free at:

http://stock-callers.com/registration

Emergent BioSolutions

Maryland headquartered Emergent BioSolutions Inc.'s stock finished Tuesday's session 2.15% lower at $30.00. A total volume of 577,222 shares was traded, which was above their three months average volume of 483,090 shares. The Company's shares have advanced 2.60% over the previous three months. The stock is trading below its 50-day moving average by 2.02%. Furthermore, shares of Emergent BioSolutions, which focuses on the development, manufacture, and distribution of a portfolio of vaccines, therapeutics, and other novel products and related services for civilian and military populations in the US, have a Relative Strength Index (RSI) of 40.47.

On January 09^th, 2017, Emergent BioSolutions, under its preliminary unaudited 2016 financial results announced that on a combined basis, the Company anticipates FY16 total revenue of $500 million to $505 million, the midpoint of which represents a $20 million decline from FY15. On a combined basis, the Company anticipates FY16 net income of $44 to $48 million. For Q1 2017, the Company anticipates total revenues of $120 million to $135 million. Your complete research report on EBS can be retrieved for free at:

http://stock-callers.com/registration/?symbol=EBS

Chimerix

Shares in Durham, North Carolina headquartered Chimerix Inc. ended at $4.77, down 1.65% from the last trading session. The stock recorded a trading volume of 341,702 shares. The Company's shares have gained 5.30% in the last one month, 5.53% over the previous three months, and 3.70% since the start of this year. The stock is trading 0.62% above its 50-day moving average and 0.36% above its 200-day moving average. Moreover, shares of Chimerix, which discovers, develops, and commercializes oral antivirals in the areas of unmet medical needs in the US, have an RSI of 49.24.

On January 06^th, 2017, Chimerix announced preliminary data from an ongoing Phase-1 study to investigate the safety, tolerability and plasma/intracellular concentration of intravenous (IV) brincidofovir (BCV) following single escalating doses in healthy adult subjects. The Company stated that in this ongoing study, IV administration of BCV demonstrated a favorable tolerability profile at both doses tested to date. No drug related adverse events or laboratory abnormalities were identified. Notably, gastrointestinal side effects were absent. Blood plasma concentrations of BCV which have previously demonstrated anti-viral potency in cytomegalovirus prevention and adenovirus treatment were achieved with IV doses that were one tenth of those required with oral dosing. CMRX free report is just a click away at:

http://stock-callers.com/registration/?symbol=CMRX

VIVUS

Mountain View, California headquartered VIVUS Inc.'s stock ended yesterday's session 0.83% lower at $1.19, with a total trading volume of 160,002 shares. The Company's shares have advanced 12.26% in the previous three months and 3.48% on an YTD basis. The stock is trading 2.86% below its 200-day moving average. Additionally, shares of VIVUS, which develops and commercializes therapies to address unmet medical needs in the US and the European Union, have an RSI of 46.37.

On January 09^th, 2017, VIVUS and Selten Pharma, Inc., announced VIVUS' acquisition from Selten of exclusive, worldwide rights for the development and commercialization of tacrolimus and ascomycin for the treatment of Pulmonary Arterial Hypertension and related vascular diseases. VIVUS assumes all development and commercialization responsibilities. Sign up for your complimentary research report on VVUS at:

http://stock-callers.com/registration/?symbol=VVUS

RXi Pharma

At the close on Tuesday, shares in Marlborough, Massachusetts headquartered RXi Pharmaceuticals Corp. recorded a trading volume of 1.91 million shares, which was above their three months average volume of 714,690 shares. The stock finished 0.16% lower at $0.75. The Company's shares have gained 4.46% since the start of this year. The stock is trading below its 50-day moving average by 37.71%. Furthermore, shares of RXi Pharma, which focuses on discovering and developing therapies primarily in the areas of dermatology and ophthalmology, have an RSI of 42.85.

On January 09^th, 2017, RXi Pharma announced the closing of its acquisition of all of the outstanding capital stock of MirImmune Inc., a privately-held company. Under terms of the stock purchase agreement, MirImmune's shareholders will initially receive a total of approximately 2.75 million shares of the Company's common stock and an additional 1.1 million shares of Series C Preferred Stock, which is convertible 1:1 into common stock, subject to receipt of stockholder approval. Register for free on Stock-Callers.com and download the latest research report on RXII at:

http://stock-callers.com/registration/?symbol=RXII

Stock Callers:

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

SC has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

http://stock-callers.com/legal-disclaimer/

CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected]
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.